Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2.
Front Immunol
; 15: 1416375, 2024.
Article
in En
| MEDLINE
| ID: mdl-39131158
ABSTRACT
With the rapid global spread of COVID-19 and the continuous emergence of variants, there is an urgent need to develop safe and effective vaccines. Here, we developed a novel mRNA vaccine, HC009, based on new formulation by the QTsome delivery platform. Immunogenicity results showed that the prime-boost immunization strategy with HC009 was able to induce robust and durable humoral immunity, as well as Th1-biased cellular responses in rodents or non-human primates (NHPs). After further challenge with live SARS-CoV-2 virus, HC009 provided adequate protection against virus infection in hACE2 transgenic mice. Therefore, HC009 could provide significant immune protection against SARS-CoV-2.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Mice, Transgenic
/
Immunogenicity, Vaccine
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
/
MRNA Vaccines
/
Antibodies, Viral
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Front Immunol
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: